Table of Content

1 Key Insights

2 Keratoconus (KC) Market Overview at a Glance
2.1 Market Share (%) Distribution of Keratoconus (KC) in 2017
2.2 Market Share (%) Distribution of Keratoconus (KC) in 2030

3 Executive Summary of Keratoconus (KC)

4 Disease Background and Overview: Keratoconus (KC)
4.1 Introduction
4.2 Types of KC
4.2.1 Shape-based differentiation
4.2.2 Severity- based differentiation
4.2.3 Index-based differentiation
4.3 Causes
4.4 Signs and Symptoms
4.5 Pathology
4.6 Histopathology
4.6.1 Epithelium
4.6.2 Basement membrane
4.6.3 Nerve fibers
4.6.4 Bowman’s layer
4.6.5 Stroma
4.7 Diagnosis
4.7.1 Eye refraction
4.7.2 Slit-lamp examination
4.7.3 Keratometry
4.7.4 Corneal Topography
4.7.5 Corneal Tomography
4.7.6 Keratoconus indices
4.7.7 The Belin Ambrosio Enhanced Ectasia Display (BAD)
4.7.8 Holladay 6 map display
4.7.9 Corneal pachymetry
4.7.10 Automated detection program for subclinical KC
4.7.11 Corneal biomechanics
4.8 Differential Diagnosis

5 Epidemiology and Patient Population
5.1 Key Findings
5.2 Total Diagnosed Prevalent Population of Keratoconus in the 7MM

6 Country-wise Epidemiology of Keratoconus
6.1 United States
6.1.1 Assumptions and Rationale
6.1.2 Total Diagnosed Prevalent Population of Keratoconus in the United States
6.1.3 Severity-specific Distribution of Keratoconus in the United States
6.1.4 Age-specific Distribution of Keratoconus in the United States
6.2 EU5 Countries
6.2.1 Assumptions and Rationale
6.3 Germany
6.3.1 Total Diagnosed Prevalent Population of Keratoconus in Germany
6.3.2 Severity-specific Distribution of Keratoconus in Germany
6.3.3 Age-specific Distribution of Keratoconus in Germany
6.4 France
6.4.1 Total Diagnosed Prevalent Population of Keratoconus in France
6.4.2 Severity-specific Distribution of Keratoconus in France
6.4.3 Age-specific Distribution of Keratoconus in France
6.5 Italy
6.5.1 Total Diagnosed Prevalent Population of Keratoconus in Italy
6.5.2 Severity-specific Distribution of Keratoconus in Italy
6.5.3 Age-specific Distribution of Keratoconus in Italy
6.6 Spain
6.6.1 Total Diagnosed Prevalent Population of Keratoconus in Spain
6.6.2 Severity-specific Distribution of Keratoconus in Spain
6.6.3 Age-specific Distribution of Keratoconus in Spain
6.7 United Kingdom
6.7.1 Total Diagnosed Prevalent Population of Keratoconus in the United Kingdom
6.7.2 Severity-specific Distribution of Keratoconus in the United Kingdom
6.7.3 Age-specific Distribution of Keratoconus in the United Kingdom
6.8 Japan
6.8.1 Assumptions and Rationale
6.8.2 Total Diagnosed Prevalent Population of Keratoconus in Japan
6.8.3 Severity-specific Distribution of Keratoconus in Japan
6.8.4 Age-specific Distribution of Keratoconus in Japan

7 Treatment
7.1 Spectacles and Contact Lenses in Keratoconus
7.2 Intrastromal Corneal Ring Segments (ICRS)
7.3 Keratoplasty: Penetrating Keratoplasty (PK)?Deep Anterior Lamellar Keratoplasty (DALK)
7.4 Corneal Cross-Linking (CXL)
7.4.1 Corneal cross-linking Plus
7.4.2 Accelerated Cross-Linking
7.5 Future of Keratoconus Treatment
7.5.1 Pulse CXL
7.5.2 Epi-on Cross-Linking
7.5.3 CXL Using Topography-Guided UV-A Energy Emission
7.5.4 Bowman Layer Transplantation
7.6 Conclusion

8 Photochemical corneal collagen cross linkage using riboflavin and ultraviolet A for keratoconus and keratectasia
8.1 Recommendation
8.2 Indications and current treatments
8.3 The Procedures
8.4 Efficacy
8.4.1 Epithelium off CXL
8.4.2 Epithelium off CXL in combination with other interventions (CXL plus)
8.4.3 Epithelium-on (transepithelial) CXL with or without additional interventions (CXL plus)
8.5 Safety

9 Treatment Algorithm

10 Recognized Establishments

11 Unmet Needs

12 Marketed and Emerging Therapies
12.1 Key Cross Competition
12.2 Photrexa Viscous and Photrexa: Glaukos/Avedro
12.2.1 Drug Description
12.2.2 Regulatory Milestones
12.2.3 Other Development Activities
12.2.4 Safety and Efficacy
12.2.5 Product Profile
12.3 CE Marked Riboflavin Formulations: Avedro/ Glaukos Corporation
12.3.1 Drug Description
12.3.2 Other Development Activities
12.3.3 Clinical Development
12.3.4 Product Profile
12.4 Ricrolin: Sooft Italia
12.4.1 Drug Description
12.4.2 Other Development Activities
12.4.3 Safety and Efficacy
12.4.4 Product Profile
12.5 Collagex Riboflavin: Lightmed_OptiMed
12.5.1 Drug Description
12.5.2 Product Profile
12.6 Peschke Riboflavin Solutions: Peschke Meditrade GmbH
12.6.1 Drug Description
12.6.2 Product Profile

13 Emerging Drug
13.1 IVMED-80: iVeena Delivery Systems
13.1.1 Drug Description
13.1.2 Other Development Activities
13.1.3 Clinical Development
13.1.4 Safety and Efficacy
13.1.5 Product Profile

14 Keratoconus (KC): Seven Major Market Analysis
14.1 Key Findings
14.2 Market Size of Keratoconus (KC) in the 7MM

15 7MM Market Outlook

16 United States Market Size
16.1.1 The total market size of Keratoconus (KC)
16.1.2 Market Size by Therapies
16.2 EU5 Market Size
16.3 Germany
16.3.1 The total market size of Keratoconus (KC)
16.3.2 Market Size by Therapies
16.4 France
16.4.1 The total market size of Keratoconus (KC)
16.4.2 Market Size by Therapies
16.5 Italy
16.5.1 The total market size of Keratoconus (KC)
16.5.2 Market Size by Therapies
16.6 Spain
16.6.1 The total market size of Keratoconus (KC)
16.6.2 Market Size by Therapies
16.7 United Kingdom
16.7.1 The total market size of Keratoconus (KC)
16.7.2 Market Size by Therapies
16.8 Japan Market Size
16.8.1 The total market size of Keratoconus (KC)
16.8.2 Market Size by Therapies

17 Market Access and Reimbursement

18 Market Drivers

19 Market Barriers

20 SWOT Analysis

21 Appendix
21.1 Bibliography
21.2 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight



List of Figures


Figure 1 Total Diagnosed Prevalent Population of Keratoconus in the 7MM (2017–2030)
Figure 2 Total Diagnosed Prevalent Population of Keratoconus in the United States (2017–2030)
Figure 3 Severity-specific Distribution of Keratoconus in the United States (2017–2030)
Figure 4 Age-specific Distribution of Keratoconus in the United States (2017–2030)
Figure 5 Total Diagnosed Prevalent Population of Keratoconus in Germany (2017–2030)
Figure 6 Severity-specific Distribution of Keratoconus in Germany (2017–2030)
Figure 7 Age-specific Distribution of Keratoconus in Germany (2017–2030)
Figure 8 Total Diagnosed Prevalent Population of Keratoconus in France (2017–2030)
Figure 9 Severity-specific Distribution of Keratoconus in France (2017–2030)
Figure 10 Age-specific Distribution of Keratoconus in France (2017–2030)
Figure 11 Total Diagnosed Prevalent Population of Keratoconus in Italy (2017–2030)
Figure 12 Severity-specific Distribution of Keratoconus in Italy (2017–2030)
Figure 13 Age-specific Distribution of Keratoconus in Italy (2017–2030)
Figure 14 Total Diagnosed Prevalent Population of Keratoconus in Spain (2017–2030)
Figure 15 Severity-specific Distribution of Keratoconus in Spain (2017–2030)
Figure 16 Age-specific Distribution of Keratoconus in Spain (2017–2030)
Figure 17 Total Diagnosed Prevalent Population of Keratoconus in the United Kingdom (2017–2030)
Figure 18 Severity-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Figure 19 Age-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Figure 20 Total Diagnosed Prevalent Population of Keratoconus in Japan (2017–2030)
Figure 21 Severity-specific Distribution of Keratoconus in Japan (2017–2030)
Figure 22 Age-specific Distribution of Keratoconus in Japan (2017–2030)
Figure 23 Keratoconus Treatment Algorithm
Figure 24 Unmet Needs of KC
Figure 25 Seven Major Market Size of Keratoconus (KC) in USD Million (2017–2030)
Figure 26 Total Market Size of Keratoconus (KC) in the United States, USD Millions (2017–2030)
Figure 27 Market size of Keratoconus (KC) by therapies in the United States, in USD Million (2017–2030)
Figure 28 Total Market Size of Keratoconus (KC) in Germany, USD Millions (2017–2030)
Figure 29 Market size of Keratoconus (KC) by therapies in Germany, in USD Million (2017–2030)
Figure 30 Total Market Size of Keratoconus (KC) in France, USD Millions (2017–2030)
Figure 31 Market size of Keratoconus (KC) by therapies in France, in USD Million (2017–2030)
Figure 32 Total Market Size of Keratoconus (KC) in Italy, USD Millions (2017–2030)
Figure 33 Market size of Keratoconus (KC) by therapies in Italy, in USD Million (2017–2030)
Figure 34 Total Market Size of Keratoconus (KC) in Spain, USD Millions (2017–2030)
Figure 35 Market size of Keratoconus (KC) by therapies in Spain, in USD Million (2017–2030)
Figure 36 Total Market Size of Keratoconus (KC) in the United Kingdom, USD Millions (2017–2030)
Figure 37 Market size of Keratoconus (KC) by therapies in the United Kingdom, in USD Million (2017–2030)
Figure 38 Total Market Size of Keratoconus (KC) in Japan, USD Millions (2017–2030)
Figure 39 Market size of Keratoconus (KC) by therapies in Japan, in USD Million (2017–2030)
Figure 40 Market Drivers
Figure 41 Market Barriers
Figure 42 SWOT Analysis

 

List of Tables


Table 1 Summary of KC, Market, Epidemiology and Key Events (2017–2030)
Table 2 Amsler-Krumeich Classification for grading KC
Table 3 ABCD Grading System for classifying KC
Table 4 Total Diagnosed Prevalent Population of Keratoconus in the 7MM (2017–2030)
Table 5 Total Diagnosed Prevalent Population of Keratoconus in the United States (2017–2030)
Table 6 Severity-specific Distribution of Keratoconus in the United States (2017–2030)
Table 7 Age-specific Distribution of Keratoconus in the United States (2017–2030)
Table 8 Total Diagnosed Prevalent Population of Keratoconus in Germany (2017–2030)
Table 9 Severity-specific Distribution of Keratoconus in Germany (2017–2030)
Table 10 Age-specific Distribution of Keratoconus in Germany (2017–2030)
Table 11 Total Diagnosed Prevalent Population of Keratoconus in France (2017–2030)
Table 12 Severity-specific Distribution of Keratoconus in France (2017–2030)
Table 13 Age-specific Distribution of Keratoconus in France (2017–2030)
Table 14 Total Diagnosed Prevalent Population of Keratoconus in Italy (2017–2030)
Table 15 Severity-specific Distribution of Keratoconus in Italy (2017–2030)
Table 16 Age-specific Distribution of Keratoconus in Italy (2017–2030)
Table 17 Total Diagnosed Prevalent Population of Keratoconus in Spain (2017–2030)
Table 18 Severity-specific Distribution of Keratoconus in Spain (2017–2030)
Table 19 Age-specific Distribution of Keratoconus in Spain (2017–2030)
Table 20 Total Diagnosed Prevalent Population of Keratoconus in the United Kingdom (2017–2030)
Table 21 Severity-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Table 22 Age-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Table 23 Total Diagnosed Prevalent Population of Keratoconus in Japan (2017–2030)
Table 24 Severity-specific Distribution of Keratoconus in Japan (2017–2030)
Table 25 Age-specific Distribution of Keratoconus in Japan (2017–2030)
Table 26 Paracel; Clinical Trial Description,2020
Table 27 Seven Major Market Size of Keratoconus (KC) in USD Million (2017–2030)
Table 28 Total Market Size of Keratoconus (KC) in the United States, in USD Million (2017–2030)
Table 29 Market size of Keratoconus (KC) by therapies in the United States, in USD Million (2017–2030)
Table 30 Total Market Size of Keratoconus (KC) in Germany, in USD Million (2017–2030)
Table 31 Market size of Keratoconus (KC) by therapies in Germany, in USD Million (2017–2030)
Table 32 Total Market Size of Keratoconus (KC) in France, in USD Million (2017–2030)
Table 33 Market size of Keratoconus (KC) by therapies in France, in USD Million (2017–2030)
Table 34 Total Market Size of Keratoconus (KC) in Italy, in USD Million (2017–2030)
Table 35 Market size of Keratoconus (KC) by therapies in Italy, in USD Million (2017–2030)
Table 36 Total Market Size of Keratoconus (KC) in Spain, in USD Million (2017–2030)
Table 37 Market size of Keratoconus (KC) by therapies in Spain, in USD Million (2017–2030)
Table 38 Total Market Size of Keratoconus (KC) in the United Kingdom, in USD Million (2017–2030)
Table 39 Market size of Keratoconus (KC) by therapies in the United Kingdom, in USD Million (2017–2030)
Table 40 Total Market Size of Keratoconus (KC) in Japan, in USD Million (2017–2030)
Table 41 Market size of Keratoconus (KC) by therapies in Japan, in USD Million (2017–2030)